Scholar Rock (NASDAQ:SRRK) Price Target Raised to $50.00

Scholar Rock (NASDAQ:SRRK) had its price objective raised by HC Wainwright from $40.00 to $50.00 in a research note released on Tuesday morning, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Scholar Rock’s FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at $0.18 EPS.

A number of other brokerages have also weighed in on SRRK. JPMorgan Chase & Co. lifted their price objective on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, October 14th. Wedbush lifted their price target on shares of Scholar Rock from $40.00 to $47.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Piper Sandler upped their price objective on shares of Scholar Rock from $28.00 to $42.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. BMO Capital Markets boosted their price target on shares of Scholar Rock from $34.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, October 11th. Finally, Truist Financial raised their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Stock Performance

Scholar Rock stock opened at $39.90 on Tuesday. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $43.38. The firm has a market cap of $3.74 billion, a P/E ratio of -16.23 and a beta of 0.47. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm has a 50-day moving average of $24.88 and a 200-day moving average of $14.70.

Insider Buying and Selling

In other news, Director Srinivas Akkaraju sold 1,175,713 shares of Scholar Rock stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $29.25, for a total transaction of $34,389,605.25. Following the completion of the transaction, the director now directly owns 5,612,896 shares in the company, valued at approximately $164,177,208. This trade represents a 17.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tracey Sacco sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $25.62, for a total value of $768,600.00. Following the completion of the sale, the insider now directly owns 49,285 shares in the company, valued at approximately $1,262,681.70. This represents a 37.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,823,322 shares of company stock valued at $56,411,627 over the last quarter. Corporate insiders own 19.20% of the company’s stock.

Hedge Funds Weigh In On Scholar Rock

Several large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. grew its position in Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock valued at $25,000 after purchasing an additional 514 shares during the last quarter. Quarry LP raised its holdings in Scholar Rock by 3,443.3% in the 3rd quarter. Quarry LP now owns 4,500 shares of the company’s stock worth $36,000 after acquiring an additional 4,373 shares during the last quarter. Walleye Trading LLC purchased a new stake in Scholar Rock during the 1st quarter valued at $178,000. Principal Financial Group Inc. bought a new stake in shares of Scholar Rock in the 2nd quarter worth $98,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Scholar Rock in the second quarter worth $100,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.